BeiGene, Ltd. ( (ONC) ) has released its Q2 earnings. Here is a breakdown of the information BeiGene, Ltd. presented to its investors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeOne Medicines Ltd., a global oncology company, focuses on developing innovative treatments for cancer patients worldwide, with a diverse portfolio spanning hematology and solid tumors. In the second quarter of 2025, BeOne reported a 42% increase in total revenues, reaching $1.3 billion, primarily driven by the growth of BRUKINSA sales in the U.S. and Europe. The company also achieved a significant improvement in GAAP net income, reporting $94 million compared to a loss in the previous year, and adjusted net income surged by 985%. Operating expenses rose due to investments in R&D and global commercial expansion.
Key financial highlights include a 49% increase in global BRUKINSA revenues to $950 million and a 22% growth in TEVIMBRA sales. The company maintained a strong gross margin of 87.4% and reported a free cash flow of $220 million. BeOne anticipates over 20 milestones in the next 18 months, focusing on expanding its hematology and solid tumor pipeline, with significant advancements expected in clinical trials and regulatory approvals.
Looking forward, BeOne remains optimistic about its growth trajectory, with updated full-year 2025 revenue guidance between $5.0 billion and $5.3 billion, driven by BRUKINSA’s leadership and global expansion. The company plans to continue investing in R&D and commercial operations to support sustainable growth and deliver transformative medicines to more patients worldwide.